Current and future use of angiotensin II receptor blockers in patients with COVID-19
No scientific evidence for the negative influence of angiotensin II receptor blockers onto COVID-19 clinical course has been identified so far. Prescribing angiotensin II receptor blockers as COVID-19 pathogenetic therapy could only be considered within clinical trials. Patients who have been taking...
| Hlavní autoři: | , , |
|---|---|
| Médium: | Článek |
| Jazyk: | Russian |
| Vydáno: |
Izdatelstvo OKI
2020-10-01
|
| Edice: | Качественная клиническая практика |
| Témata: | |
| On-line přístup: | https://www.clinvest.ru/jour/article/view/521 |